<!DOCTYPE html><html><head><style>
      /* Create a running element */
      #header-and-footer {
        position: running(header-and-footer);
        text-align: right;
      }

      /* Add that running element to the top and bottom of every page */
      @page {
        @top {
          content: element(header-and-footer);
        }
        @bottom {
          content: element(header-and-footer);
        }
      }

      /* Add a page number */
      #page-number {
        content: "Page " counter(page);
      }

      /* Create a title page with a full-bleed background and no header */
      #title-page {
        page: title-page;
      }

      @page title-page {
        @top {
          content: "";
        }
      }

      #title-page h1 {
        padding: 200px 0 40px 0;
        font-size: 30px;
      }

      /* Dynamically create a table of contents with leaders */
      #table-of-contents a {
        content: target-content(attr(href)) leader('.') target-counter(attr(href), page);
        color: #135697;
        text-decoration: none;
        display: block;
        padding-top: 5px;
      }

      /* Float the footnote to a footnotes area on the page */
      .footnote {
        float: footnote;
        font-size: small;
      }

      .page {
        page-break-after: always;
      }

      body {
        counter-reset: chapter;
        font-family: 'Open Sans';
        color: #135697;
      }
    </style>
    <link href='https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;600;800&display=swap' rel='stylesheet'>
    </style></head><body>
      <div id="title-page" class="page">
        <h1>Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer\’s Disease</h1>
        <div id="header-and-footer">
          <span id="page-number"></span>
        </div>
      </div>
      <div id="toc-page" class="page">
        <div id="table-of-contents">
          <a href="#section-1"></a><a href="#section-2"></a><a href="#section-3"></a><a href="#section-4"></a><a href="#section-5"></a><a href="#section-6"></a><a href="#section-7"></a><a href="#section-8"></a><a href="#section-9"></a><a href="#section-10"></a><a href="#section-11"></a><a href="#section-12"></a><a href="#section-13"></a><a href="#section-14"></a><a href="#section-15"></a>
        </div>
        <div id="header-and-footer">
          <span id="page-number"></span>
        </div>
      </div>
    <div class="page"><h1 id="section-1">1&nbspPROTOCOL SUMMARY</h1><div class=""><h2 id="section-1.1">1.1&nbspProtocol Synopsis</h2></div><div class=""><h2 id="section-1.2">1.2&nbspTrial Schema</h2></div><div class=""><h2 id="section-1.3">1.3&nbspSchedule of Activities</h2></div></div><div class="page"><h1 id="section-2">2&nbspINTRODUCTION</h1><div class=""><h2 id="section-2.1">2.1&nbspPurpose of Trial</h2></div><div class=""><h2 id="section-2.2">2.2&nbspSummary of Benefits and Risks</h2></div></div><div class="page"><h1 id="section-3">3&nbspTRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS</h1></div><div class="page"><h1 id="section-4">4&nbspTRIAL DESIGN</h1><div class=""><h2 id="section-4.1">4.1&nbspDescription of Trial Design</h2><div class=""><h3 id="section-4.1.1">4.1.1&nbspParticipant Input into Design</h3></div></div><div class=""><h2 id="section-4.2">4.2&nbspRationale for Trial Design</h2><div class=""><h3 id="section-4.2.1">4.2.1&nbspRationale for Comparator</h3></div><div class=""><h3 id="section-4.2.2">4.2.2&nbspRationale for Adaptive or Novel Trial Design</h3></div><div class=""><h3 id="section-4.2.3">4.2.3&nbspOther Trial Design Considerations</h3></div></div><div class=""><h2 id="section-4.3">4.3&nbspAccess to Trial Intervention After End of Trial</h2></div><div class=""><h2 id="section-4.4">4.4&nbspStart of Trial and End of Trial</h2></div></div><div class="page"><h1 id="section-5">5&nbspTRIAL POPULATION</h1><div class=""><h2 id="section-5.1">5.1&nbspSelection of Trial Population</h2></div><div class=""><h2 id="section-5.2">5.2&nbspRationale for Trial Population</h2></div><div class=""><h2 id="section-5.3">5.3&nbspInclusion Criteria</h2><p>Patients may be included in the study only if they meet <strong>all</strong> the following criteria:</p>
<table>
  <tr>
    <td style="vertical-align: top">[1]</td>
    <td style="vertical-align: top">
      Males and postmenopausal females at least 50 years of age.
    </td>
  </tr>
  <tr>
    <td style="vertical-align: top">[2]</td>
    <td style="vertical-align: top">Diagnosis of probable AD as defined by National Institute of Neurological and Communicative Disorders and Stroke
      (NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA) guidelines (Attachment LZZT.7).
  </tr>
  <tr>
    <td style="vertical-align: top">[3]</td>
    <td style="vertical-align: top">MMSE score of 10 to 23.</td> 
  </tr>
  <tr>
    <td style="vertical-align: top">[4]</td>
    <td style="vertical-align: top">Hachinski Ischemic Scale score of ≤4 (Attachment LZZT.8).</td>
  </tr>
  <tr>
    <td style="vertical-align: top">[5]</td>
    <td style="vertical-align: top">CNS imaging (CT scan or MRI of brain) compatible with AD within past 1 year.
      The following findings are incompatible with AD:
      <ol type="a">
        <li>Large vessel strokes
          <ol type="1">
            <li>Any definite area of encephalomalacia consistent with ischemic necrosis in any cerebral artery
              territory.</li>
            <li>Large, confluent areas of encephalomalacia in parieto-occipital or frontal regions consistent with
              watershed infarcts. The above are exclusionary. Exceptions are made for small areas of cortical asymmetry
              which may represent a small cortical stroke or a focal area of atrophy provided there is no abnormal
              signal intensity in the immediately underlying parenchyma. Only one such questionable area allowed per
              scan, and size is restricted to ≤1cm in frontal/parietal/temporal cortices and ≤2 cm in occipital cortex.
            </li>
          </ol>
        </li>
        <li>Small vessel ischemia
          <ol type="1">
            <li>Lacunar infarct is defined as an area of abnormal intensity seen on CT scan or on both T1 and T2
              weighted MRI images in the basal ganglia, thalamus or deep white matter which is ≤1 cm in maximal
              diameter. A maximum of one lacune is allowed per scan.</li>
            <li>Leukoariosis or leukoencephalopathy is regarded as an abnormality seen on T2 but not T1 weighted MRIs,
              or on CT. This is accepted if mild or moderate in extent, meaning involvement of less than 25% of cortical
              white matter.</li>
          </ol>
        </li>
        <li>Miscellaneous
          <ol type="1">
            <li>Benign small extra-axial tumors (ie, meningiomas) are accepted if they do not contact or indent the
              brain parenchyma.</li>
            <li>extra-axial arachnoid cysts are accepted if they do not indent or deform the brain parenchyma.</li>
          </ol>
        </li>
      </ol>
    </td>
  </tr>
  <tr>
    <td style="vertical-align: top">[6]</td>
    <td style="vertical-align: top">Investigator has obtained informed consent signed by the patient (and/or legal representative) and by the
      caregiver.</td>
  </tr>
  <tr>
    <td style="vertical-align: top">[7]</td>
    <td style="vertical-align: top">Geographic proximity to investigator’s site that allows adequate follow-up.</td>
  </tr>
  <tr>
    <td style="vertical-align: top">[8]</td>
    <td style="vertical-align: top">A reliable caregiver who is in frequent or daily contact with the patient and who will accompany the patient to
      the office and/or be available by telephone at designated times, will monitor administration of prescribed
      medications, and will be responsible for the overall care of the patient at home. The caregiver and the patient
      must be able to communicate in English and willing to comply with 26 weeks of transdermal therapy.</td>
  </tr>
<table></div><div class=""><h2 id="section-5.4">5.4&nbspExclusion Criteria</h2></div><div class=""><h2 id="section-5.5">5.5&nbspLifestyle Considerations</h2><div class=""><h3 id="section-5.5.1">5.5.1&nbspMeals and Dietary Restrictions</h3></div><div class=""><h3 id="section-5.5.2">5.5.2&nbspCaffeine, Alcohol, Tobacco, and Other Habits</h3></div><div class=""><h3 id="section-5.5.3">5.5.3&nbspPhysical Activity</h3></div><div class=""><h3 id="section-5.5.4">5.5.4&nbspOther Activity</h3></div></div><div class=""><h2 id="section-5.6">5.6&nbspScreen Failures</h2></div></div><div class="page"><h1 id="section-6">6&nbspTRIAL INTERVENTION AND CONCOMITANT THERAPY</h1><div class=""><h2 id="section-6.1">6.1&nbspDescription of Trial Intervention</h2></div><div class=""><h2 id="section-6.2">6.2&nbspRationale for Trial Intervention</h2></div><div class=""><h2 id="section-6.3">6.3&nbspDosing and Administration</h2><div class=""><h3 id="section-6.3.1">6.3.1&nbspTrial Intervention Dose Modification</h3></div></div><div class=""><h2 id="section-6.4">6.4&nbspTreatment of Overdose</h2></div><div class=""><h2 id="section-6.5">6.5&nbspPreparation, Handling, Storage and Accountability</h2><div class=""><h3 id="section-6.5.1">6.5.1&nbspPreparation of Trial Intervention</h3></div><div class=""><h3 id="section-6.5.2">6.5.2&nbspHandling and Storage of Trial Intervention</h3></div><div class=""><h3 id="section-6.5.3">6.5.3&nbspAccountability of Trial Intervention</h3></div></div><div class=""><h2 id="section-6.6">6.6&nbspParticipant Assignment, Randomisation and Blinding</h2><div class=""><h3 id="section-6.6.1">6.6.1&nbspParticipant Assignment</h3></div><div class=""><h3 id="section-6.6.2">6.6.2&nbspRandomisation</h3></div><div class=""><h3 id="section-6.6.3">6.6.3&nbspBlinding and Unblinding</h3><p>The study will be double-blind. To further preserve the blinding of the study, only a minimum number of Lilly and CRO personnel will see the randomization table and codes before the study is complete.</p>
<p>Emergency codes generated by a computer drug-labeling system will be available to the investigator. These codes, which reveal the patients treatment group, may be opened during the study only if the choice of follow-up treatment depends on the patient’s therapy assignment.</p>
<p>The investigator should make every effort to contact the clinical research physician prior to unblinding a patient’s therapy assignment. If a patient’s therapy assignment is unblinded, Lilly must be notified immediately by telephone. After the study, the investigator must return all sealed and any opened codes.</p></div></div><div class=""><h2 id="section-6.7">6.7&nbspTrial Intervention Compliance</h2></div><div class=""><h2 id="section-6.8">6.8&nbspConcomitant Therapy</h2><div class=""><h3 id="section-6.8.1">6.8.1&nbspProhibited Concomitant Therapy</h3></div><div class=""><h3 id="section-6.8.2">6.8.2&nbspPermitted Concomitant Therapy</h3></div><div class=""><h3 id="section-6.8.3">6.8.3&nbspRescue Therapy</h3></div><div class=""><h3 id="section-6.8.4">6.8.4&nbspOther Therapy</h3></div></div></div><div class="page"><h1 id="section-7">7&nbspDISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL</h1><div class=""><h2 id="section-7.1">7.1&nbspDiscontinuation of Trial Intervention</h2><div class=""><h3 id="section-7.1.1">7.1.1&nbspCriteria for Permanent Discontinuation of Trial Intervention</h3></div><div class=""><h3 id="section-7.1.2">7.1.2&nbspTemporary Discontinuation or Interruption of Trial Intervention</h3></div><div class=""><h3 id="section-7.1.3">7.1.3&nbspRechallenge</h3></div></div><div class=""><h2 id="section-7.2">7.2&nbspParticipant Withdrawal from the Trial</h2></div><div class=""><h2 id="section-7.3">7.3&nbspLost to Follow-Up</h2></div><div class=""><h2 id="section-7.4">7.4&nbspTrial Stopping Rules</h2></div></div><div class="page"><h1 id="section-8">8&nbspTRIAL ASSESSMENTS AND PROCEDURES</h1><div class=""><h2 id="section-8.1">8.1&nbspScreening/Baseline Assessments and Procedures</h2></div><div class=""><h2 id="section-8.2">8.2&nbspEfficacy Assessments and Procedures</h2></div><div class=""><h2 id="section-8.3">8.3&nbspSafety Assessments and Procedures</h2><div class=""><h3 id="section-8.3.1">8.3.1&nbspPhysical Examination</h3></div><div class=""><h3 id="section-8.3.2">8.3.2&nbspVital Signs</h3></div><div class=""><h3 id="section-8.3.3">8.3.3&nbspElectrocardiograms</h3></div><div class=""><h3 id="section-8.3.4">8.3.4&nbspClinical Laboratory Assessments</h3></div><div class=""><h3 id="section-8.3.5">8.3.5&nbspSuicidal Ideation and Behaviour Risk Monitoring</h3></div></div><div class=""><h2 id="section-8.4">8.4&nbspAdverse Events and Serious Adverse Events</h2><div class=""><h3 id="section-8.4.1">8.4.1&nbspDefinitions of AE and SAE</h3></div><div class=""><h3 id="section-8.4.2">8.4.2&nbspTime Period and Frequency for Collecting AE and SAE Information</h3></div><div class=""><h3 id="section-8.4.3">8.4.3&nbspIdentifying AEs and SAEs</h3></div><div class=""><h3 id="section-8.4.4">8.4.4&nbspRecording of AEs and SAEs</h3></div><div class=""><h3 id="section-8.4.5">8.4.5&nbspFollow-up of AEs and SAEs</h3></div><div class=""><h3 id="section-8.4.6">8.4.6&nbspReporting of SAEs</h3></div><div class=""><h3 id="section-8.4.7">8.4.7&nbspRegulatory Reporting Requirements for SAEs</h3></div><div class=""><h3 id="section-8.4.8">8.4.8&nbspSerious and Unexpected Adverse Reaction Reporting</h3></div><div class=""><h3 id="section-8.4.9">8.4.9&nbspAdverse Events of Special Interest</h3></div><div class=""><h3 id="section-8.4.10">8.4.10&nbspDisease-related Events or Outcomes Not Qualifying as AEs or SAEs</h3></div></div><div class=""><h2 id="section-8.5">8.5&nbspPregnancy and Postpartum Information</h2><div class=""><h3 id="section-8.5.1">8.5.1&nbspParticipants Who Become Pregnant During the Trial</h3></div><div class=""><h3 id="section-8.5.2">8.5.2&nbspParticipants Whose Partners Become Pregnant</h3></div></div><div class=""><h2 id="section-8.6">8.6&nbspMedical Device Product Complaints for Drug/Device Combination Products</h2><div class=""><h3 id="section-8.6.1">8.6.1&nbspDefinition of Medical Device Product Complaints</h3></div><div class=""><h3 id="section-8.6.2">8.6.2&nbspRecording of Medical Device Product Complaints</h3></div><div class=""><h3 id="section-8.6.3">8.6.3&nbspTime Period and Frequency for Collecting Medical Device Product Complaints .</h3></div><div class=""><h3 id="section-8.6.4">8.6.4&nbspFollow-Up of Medical Device Product Complaints</h3></div><div class=""><h3 id="section-8.6.5">8.6.5&nbspRegulatory Reporting Requirements for Medical Device Product Complaints</h3></div></div><div class=""><h2 id="section-8.7">8.7&nbspPharmacokinetics</h2></div><div class=""><h2 id="section-8.8">8.8&nbspGenetics</h2></div><div class=""><h2 id="section-8.9">8.9&nbspBiomarkers</h2></div><div class=""><h2 id="section-8.1">8.1&nbspImmunogenicity Assessments</h2><div class=""><h3 id="section-8.1.1">8.1.1&nbspMedical Resource Utilisation and Health Economics</h3></div></div></div><div class="page"><h1 id="section-9">9&nbspSTATISTICAL CONSIDERATIONS</h1><div class=""><h2 id="section-9.1">9.1&nbspAnalysis Sets</h2></div><div class=""><h2 id="section-9.2">9.2&nbspAnalyses Supporting Primary Objective(s)</h2><div class=""><h3 id="section-9.2.1">9.2.1&nbspStatistical Model, Hypothesis, and Method of Analysis</h3></div><div class=""><h3 id="section-9.2.2">9.2.2&nbspHandling of Intercurrent Events of Primary Estimand(s)</h3></div><div class=""><h3 id="section-9.2.3">9.2.3&nbspHandling of Missing Data</h3></div><div class=""><h3 id="section-9.2.4">9.2.4&nbspSensitivity Analysis</h3></div><div class=""><h3 id="section-9.2.5">9.2.5&nbspSupplementary Analysis</h3></div></div><div class=""><h2 id="section-9.3">9.3&nbspAnalysis Supporting Secondary Objective(s)</h2></div><div class=""><h2 id="section-9.4">9.4&nbspAnalysis of Exploratory Objective(s)</h2></div><div class=""><h2 id="section-9.5">9.5&nbspSafety Analyses</h2></div><div class=""><h2 id="section-9.6">9.6&nbspOther Analyses</h2></div><div class=""><h2 id="section-9.7">9.7&nbspInterim Analyses</h2></div><div class=""><h2 id="section-9.8">9.8&nbspSample Size Determination</h2></div><div class=""><h2 id="section-9.9">9.9&nbspProtocol Deviations</h2></div></div><div class="page"><h1 id="section-10">10&nbspGENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT</h1><div class=""><h2 id="section-10.1">10.1&nbspRegulatory and Ethical Considerations</h2></div><div class=""><h2 id="section-10.2">10.2&nbspCommittees</h2></div><div class=""><h2 id="section-10.3">10.3&nbspInformed Consent Process</h2></div><div class=""><h2 id="section-10.4">10.4&nbspData Protection</h2></div><div class=""><h2 id="section-10.5">10.5&nbspEarly Site Closure or Trial Termination</h2></div></div><div class="page"><h1 id="section-11">11&nbspGENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE</h1><div class=""><h2 id="section-11.1">11.1&nbspQuality Tolerance Limits</h2></div><div class=""><h2 id="section-11.2">11.2&nbspData Quality Assurance</h2></div><div class=""><h2 id="section-11.3">11.3&nbspSource Data</h2></div></div><div class="page"><h1 id="section-12">12&nbspAPPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY</h1><div class=""><h2 id="section-12.1">12.1&nbspFurther Details and Clarifications on the AE Definition</h2></div><div class=""><h2 id="section-12.2">12.2&nbspFurther Details and Clarifications on the SAE Definition</h2></div><div class=""><h2 id="section-12.3">12.3&nbspSeverity</h2></div><div class=""><h2 id="section-12.4">12.4&nbspCausality</h2></div></div><div class="page"><h1 id="section-13">13&nbspAPPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS</h1><div class=""><h2 id="section-13.1">13.1&nbspContraception and Pregnancy Testing</h2><div class=""><h3 id="section-13.1.1">13.1.1&nbspDefinitions Related to Childbearing Potential</h3></div><div class=""><h3 id="section-13.1.2">13.1.2&nbspContraception</h3></div><div class=""><h3 id="section-13.1.3">13.1.3&nbspPregnancy Testing</h3></div></div><div class=""><h2 id="section-13.2">13.2&nbspClinical Laboratory Tests</h2></div><div class=""><h2 id="section-13.3">13.3&nbspCountry/Region-Specific Differences</h2></div><div class=""><h2 id="section-13.4">13.4&nbspPrior Protocol Amendments</h2></div></div><div class="page"><h1 id="section-14">14&nbspAPPENDIX: GLOSSARY OF TERMS</h1></div><div class="page"><h1 id="section-15">15&nbspAPPENDIX: REFERENCES</h1></div></body></html>